Please login to the form below

Not currently logged in
Email:
Password:

Aurobindo

This page shows the latest Aurobindo news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Last year, Aurobindo was given tentative FDA approval for its apixaban generic, ahead of the resolution of ongoing patent litigation.

Latest news

More from news
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    radioligands and CAR‐T for cancer. $2.1B. Sale. Aurobindo. NovartIs sold part of Sandoz’s US generics. ... Roche. Oral solid generics and dermatology business. Collaboration. $1.375B. Sandoz/ Aurobindo.

  • Deal Watch January 2017 Deal Watch January 2017

    140. Generis. Aurobindo. Company acquisition. Generic products. 135. Maverick. Takeda. Option to acquire.

  • Pharma deals in July 2015 Pharma deals in July 2015

    In early 2014 Actavis sold most of its European generics business to Aurobindo and in March 2015 completed the acquisition of Allergan.

  • Pharma deals during January 2014 Pharma deals during January 2014

    Slimming the business down a little, Actavis sold some of its generic products in France, Italy, Spain,  Portugal, Belgium, Germany and the Netherlands to Aurobindo for $41m.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Ramprasad Reddy to chair Aurobindo’s US business

    In addition, Aurobindo's board also approved that Ramprasad Reddy relinquish his executive responsibilities as full-time director of the company, although he will continue as non-exectuive director. ... Ramprasad Reddy also has roles at several other

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

Understanding behaviour change: A Porterhouse Insights specialism
...
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...